UAE Glioblastoma Multiforme Treatment Market Size & Outlook

The glioblastoma multiforme treatment market in the UAE is expected to reach a projected revenue of US$ 41.4 million by 2033. A compound annual growth rate of 7.8% is expected of the UAE glioblastoma multiforme treatment market from 2025 to 2033.
Revenue, 2024 (US$M)
$21.0
Forecast, 2033 (US$M)
$41.4
CAGR, 2025 - 2033
7.8%
Report Coverage
UAE

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

UAE glioblastoma multiforme treatment market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

UAE glioblastoma multiforme treatment market highlights

  • The UAE glioblastoma multiforme treatment market generated a revenue of USD 21.0 million in 2024 and is expected to reach USD 41.4 million by 2033.
  • The UAE market is expected to grow at a CAGR of 7.8% from 2025 to 2033.
  • In terms of segment, surgery was the largest revenue generating treatment in 2024.
  • Tumor Treating Field (TTF) Therapy is the most lucrative treatment segment registering the fastest growth during the forecast period.


Glioblastoma multiforme treatment market data book summary

Market revenue in 2024USD 21.0 million
Market revenue in 2033USD 41.4 million
Growth rate7.8% (CAGR from 2025 to 2033)
Largest segmentSurgery
Fastest growing segmentTumor Treating Field (TTF) Therapy
Historical data2021 - 2023
Base year2024
Forecast period2025 - 2033
Quantitative unitsRevenue in USD million
Market segmentationTargeted Therapy (Bevacizumab), Tumor Treating Field (TTF) Therapy, Radiation Therapy, Surgery, Chemotherapy
Key market players worldwideMerck & Co Inc, Amgen Inc, Roche, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries, Arbor Pharmaceuticals, Amneal Pharmaceuticals, Karyopharm Therapeutics Inc, Sumitomo Dainippon Pharma Oncology


Other key industry trends

  • In terms of revenue, UAE accounted for 0.6% of the global glioblastoma multiforme treatment market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Middle East & Africa, Saudi Arabia glioblastoma multiforme treatment market is projected to lead the regional market in terms of revenue in 2033.
  • Kuwait is the fastest growing regional market in Middle East & Africa and is projected to reach USD 28.0 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Glioblastoma Multiforme Treatment Market Companies

Name Profile # Employees HQ Website
Sumitomo Dainippon Pharma Oncology View profile 251-500 Cambridge, Massachusetts, United States, North America https://www.sdponcology.com/
Amneal Pharmaceuticals View profile 5001-10000 Bridgewater, New Jersey, United States, North America http://amneal.com/
Arbor Pharmaceuticals View profile 501-1000 Atlanta, Georgia, United States, North America http://www.arborpharma.com
Karyopharm Therapeutics Inc View profile 325 85 Wells Avenue, 2nd Floor, Newton, MA, United States, 02459 https://www.karyopharm.com
Roche View profile 10001+ Basel, Basel-Stadt, Switzerland, Europe http://www.roche.com
Sun Pharmaceutical Industries View profile 10001+ Mumbai, Maharashtra, India, Asia http://www.sunpharma.com
Merck & Co Inc View profile 72000 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 https://www.merck.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com
Amgen Inc View profile 26700 One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 https://www.amgen.com
Teva Pharmaceutical Industries Ltd View profile 37851 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 https://www.tevapharm.com

UAE glioblastoma multiforme treatment market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glioblastoma multiforme treatment market will help companies and investors design strategic landscapes.


Surgery was the largest segment with a revenue share of 33.81% in 2024. Horizon Databook has segmented the UAE glioblastoma multiforme treatment market based on targeted therapy (bevacizumab), tumor treating field (ttf) therapy, radiation therapy, surgery, chemotherapy covering the revenue growth of each sub-segment from 2021 to 2033.


Cancer is the leading cause of mortality in UAE. Malignant brain tumors are diagnosed in 1.4% of all cancers and responsible for 2.4% of all cancer mortality. The healthcare in UAE is regulated at both the Emirates and Federal levels. Healthcare is primarily funded by the government that delivers a high standard of care to its citizens.

Reasons to subscribe to UAE glioblastoma multiforme treatment market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of UAE glioblastoma multiforme treatment market databook

  • Our clientele includes a mix of glioblastoma multiforme treatment market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the UAE glioblastoma multiforme treatment market , including forecasts for subscribers. This country databook contains high-level insights into UAE glioblastoma multiforme treatment market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

UAE glioblastoma multiforme treatment gbm market size, by treatment, 2021-2033 (US$M)

UAE Glioblastoma Multiforme Treatment Market Outlook Share, 2024 & 2033 (US$M)

UAE glioblastoma multiforme treatment gbm market size, by treatment, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online